ArticleFrontiers in genetics2020
Identification of miRNA Biomarkers for Diverse Cancer Types Using Statistical Learning Methods at the Whole-Genome Scale.
Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial intelligence-based miRNA analysis for precision oncology: diagnostic and prognostic insights.Frontiers in molecular biosciences · 2026Review
- Improved lung cancer classification by employing diverse molecular features of microRNAs.Heliyon · 2024Article
- Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.International journal of molecular sciences · 2023Review
- Ontologies and Knowledge Graphs in Oncology Research.Cancers · 2022Review
- Identification of Potential Genomic Alterations and the circRNA-miRNA-mRNA Regulatory Network in Primary and Recurrent Synovial Sarcomas.Frontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Genome-wide analysis of miRNA molecules can reveal important information for understanding the biology of cancer. Typically, miRNAs are used as features in statistical learning methods in order to train learning models to predict cancer. This motivates us to propose a method that integrates clustering and classification techniques for diverse cancer types with survival analysis via regression to identify miRNAs that can potentially play a crucial role in the prediction of different types of tumors. Our method has two parts. The first part is a feature selection procedure, called the stochastic covariance evolutionary strategy with forward selection (SCES-FS), which is developed by integrating stochastic neighbor embedding (SNE), the covariance matrix adaptation evolutionary strategy (CMA-ES), and classifiers, with the primary objective of selecting biomarkers. SNE is used to reorder the features by performing an implicit clustering with highly correlated neighboring features. A subset of features is selected heuristically to perform multi-class classification for diverse cancer types. In the second part of our method, the most important features identified in the first part are used to perform survival analysis via Cox regression, primarily to examine the effectiveness of the selected features. For this purpose, we have analyzed next generation sequencing data from The Cancer Genome Atlas in form of miRNA expression of 1,707 samples of 10 different cancer types and 333 normal samples. The SCES-FS method is compared with well-known feature selection methods and it is found to perform better in multi-class classification for the 17 selected miRNAs, achieving an accuracy of 96%. Moreover, the biological significance of the selected miRNAs is demonstrated with the help of network analysis, expression analysis using hierarchical clustering, KEGG pathway analysis, GO enrichment analysis, and protein-protein interaction analysis. Overall, the results indicate that the 17 selected miRNAs are associated with many key cancer regulators, such as MYC, VEGFA, AKT1, CDKN1A, RHOA, and PTEN, through their targets. Therefore the selected miRNAs can be regarded as putative biomarkers for 10 types of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.